

# PRESS RELEASE



30 November, 2017, Lund, Sweden

## **The Swedish Royal Technology Mission 2017 and His Majesty King Carl XVI Gustaf of Sweden visited Immunovia yesterday**

**LUND, Sweden** — The Swedish Royal Technology Mission 2017 and **His Majesty King Carl XVI Gustaf of Sweden** as the Guest of Honor visited yesterday, the 29<sup>th</sup> of November, 2017, CREATE Health Cancer Center and four of the most innovative companies at Medicon Village. The delegation of prominent political and industry leaders included Skånes County Governor Anneli Hulthen as well as IVA President Prof Tuula Teeri. Leif Johansson, the Presiding Officer of the Royal Institute of Technology was leading the delegation.

The delegation and **His Majesty King Carl XVI Gustaf of Sweden** were introduced to the world leading research and innovation by the host Prof Carl Borrebaeck. The successful concept of Medicon Village in which innovation is brought from academic research to the patients through companies was presented by Mats Leifland and Mats Paulsson.

Four companies were chosen to present their breakthrough innovative technologies: Alligator Biosciences, Senzagen, Saga Diagnostics and Immunovia which ended the whole visit with a IMMray PanCan-d production demonstration.

Mats Grahn commented: “We were delighted to receive such a distinguished visit on our premises. Besides, we are grateful for the chance to show our state of the art technology to **His Majesty King Carl XVI Gustaf of Sweden** and the prominent delegation.” (<https://www.mediconvillage.se/sv/hm-konung-carl-xvi-gustaf-besoker-create-health>)

### **For more information, please contact:**

#### **Mats Grahn**

Chief Executive Officer, CEO, Immunovia

Tel.: +46-70-5320230

Email: mats.grahn@immunovia.com

### **About Immunovia**

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia’s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: [www.immunovia.com](http://www.immunovia.com)) Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildecos is the company’s Certified Adviser. For more information, please visit [www.immunovia.com](http://www.immunovia.com).

###